Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

OB GYN new masthead 1

March 1st, 2021

View Archives Issues

  • The Pregnancy Perspective: What Has COVID-19 Affected?

    In this cross-sectional descriptive study, women using the Ovia pregnancy app expressed receiving adequately safe maternal care during the COVID-19 pandemic, but voiced concerns related to obtaining infant supplies and prenatal education.

  • Pregnancy After Treatment for Pelvic Floor Disorders

    This consensus document was developed as a reference for physicians caring for and advising women in pregnancy following prior surgical treatment for pelvic floor disorders.

  • Is HPV Testing Superior to Pap Testing Alone in Women at Risk of Cervical Cancer?

    In this registry-based screening study of women in Catalonia, Spain, a negative human papillomavirus (HPV) and cytology co-test at baseline was associated with a cumulative incidence of cervical precancer of 0.4% at five years and 1.3% at nine years, compared to 27% among women with abnormal HPV testing at baseline.

  • Oral Progestogens for Prevention of Miscarriage

    In this double-blind, randomized clinical trial, 406 pregnant women were randomized to dydrogesterone or placebo. There were no statistically significant differences in the primary outcome (miscarriage before 20 weeks of gestation; relative risk, 0.897; 95% confidence interval, 0.548-1.467; P = 0.772), which occurred in 12.8% and 14.3% in the dydrogesterone and placebo arms, respectively. The use of dydrogesterone in women with threatened miscarriage for the prevention of early pregnancy loss in the first trimester failed to decrease the miscarriage rate or increase the live birth rate.